10 Jan 22 | CA | Alvotech and JAMP Pharma announced that Health Canada has approved Simlandi (high-concentration,...
Pearce IP BioBlast®: w/e 14 January 2021
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
Naomi is listed in IAM Patent 1000 as one of Australia's leading patent litigators. Underpinning Naomi’s legal work is a deep understanding of the pharma/biopharma industries, resulting from first hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.
See Naomi's full profile
Pearce IP BioBlast®: w/e 07 January 2021
30 Dec 21 | US | Biocon Biologics announced that the US Court of Appeals for the Federal Circuit Court has upheld the...
Pfizer quest for Samsung Bioepsis etanercept documents continues
Shortly before Christmas, the judgment handed down by Justice Burley on 18 November 2021 on a second preliminary...
Pearce IP BioBlast®: f/e 31 December 2021
20 Dec 21 | US | Sandoz announced that it has submitted a BLA to the FDA for a proposed biosimilar trastuzumab. 20 Dec...
PTE Alert (part 2): Bad Patent Term Extension Enables Generics to Avoid Preliminary Injunction in Australia
Newly appointed Justice Rofe delivered an early Christmas gift for generic and biosimilar companies in Australia in...
Pearce IP BioBlast®: w/e 17 December 2021
11 Dec 21 | Samsung Bioepis announced that SB12 (proposed eculizumab biosimilar) met all the endpoints in a Ph I...
Pearce IP BioBlast®: w/e 10 December 2021
06 Dec 21 | AU | Australia’s TGA provisionally approved Celltrion’s Regkirona® (regdanvimab) for the treatment of...
Pearce IP BioBlast®: w/e 03 December 2021
01 Dec 21 | CN | Tot Biopharm announced that China’s NMPA has approved Pusintin® (biosimilar bevacizumab) for the...
Pearce IP BioBlast®: w/e 26 November 2021
21 Nov 21 | CN | Innovent released the results of a Ph III study of sintilimab and BYVASDA® (bevacizumab biosimilar)...
Pearce IP BioBlast®: w/e 19 November 2021
15 Nov 21 | EU | Celltrion announced that the EC has approved Regkirona® (regdanvimab, CT-P59) for adults with...
Hold onto your Hats! – Expedited Patent Litigation in Australia
The speed of getting a case to trial is a key metric of any litigation system. Pharmaceutical patent litigation often...
Pearce IP BioBlast®: w/e 12 November 2021
09 Nov 21 | Coherus BioSciences reported its Q3 2021 financial results. Coherus announced that FDA review of CHS-201...
Pearce IP BioBlast®: w/e 05 November 2021
01 Nov 21 | The International Generic and Biosimilar Medicines Association called on all stakeholders ahead of its...
Pearce IP BioBlast®: w/e 29 October 2021
22 Oct 21 | Biocon released its Q2 2022 financial results, reporting a 10% increase in biosimilars revenue year on...
Pearce IP BioBlast®: w/e 22 October 2021
14 Oct 21 | Gan & Lee Pharmaceuticals announced the completion of two Ph III studies of its proposed insulin...
Strategies for generic/biosimilar market entry in Australia
Originally published in World Intellectual Property Review 3 2021 After surviving the Great Patent Cliff of 2011–2016,...